作者
H Forootan, A Sharifi, SH Mirmomen, N Daryani, H Ghofrani, M Farahvash, M Nasiri, M Talebi, A Ghavidel, H Vosoghinia, F Mansourghanaei, M Zahedi, H Mirmomen, M Azmi, M Amirian
发表日期
2005/5/10
期刊
Medical Journal of The Islamic Republic of Iran (MJIRI)
卷号
19
期号
1
页码范围
7-12
出版商
Medical Journal of The Islamic Republic of Iran (MJIRI)
简介
Background: Combination therapy with interferon and ribavirin is the most effective treatment for chronic hepatitis C today. The aim of this study was to evaluate the efficacy and safety of thrice-weekly Heberon (interferon alfa-2b) in combination with ribavirin as first-line treatment of chronic hepatitis C.
Methods: A total of97 treatment-naive patients received Heberon three million units thrice-weekly subcutaneously in combination with ribavirin for 12 months. Serum HCV RNA levels were measured before and during therapy and 6 months after the end of therapy. End-of-treatment and sustained virological responses was defmed as an undetectable HCV-RNA level at the end of treatment, and 6 months after treatment was completed (end of follow-up), respectively.
Results: In an intent-to-treat analysis, HCV-RNA was undetectable at the end of treatment in 49.5% of patients. At the end of follow-up, sustained virological …
学术搜索中的文章
H Forootan, A Sharifi, SH Mirmomen, N Daryani… - Medical Journal of The Islamic Republic of Iran (MJIRI), 2005